Philip P. Connell to Biomarkers, Tumor
This is a "connection" page, showing publications Philip P. Connell has written about Biomarkers, Tumor.
Connection Strength
0.199
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.109
-
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516.
Score: 0.090